February 2026 - Corcept Therapeutics

Relacorilant + Nab-Paclitaxel vs Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Exposure-Response

February 27, 2026

Colombo et al. • 2026 • ESGO

ROSELLA: A Phase 3 Study of Relacorilant + Nab-Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)

February 26, 2026

Lorusso et al. • 2026 • ESGO

Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study

February 20, 2026

Pivonello • 2026 • The Lancet Diabetes & Endocrinology